Cargando…

Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial

Amyloid light-chain (AL) amyloidosis is a rare, typically fatal disease characterized by the accumulation of misfolded immunoglobulin light chains (LCs). Birtamimab is an investigational humanized monoclonal antibody designed to neutralize toxic LC aggregates and deplete insoluble organ-deposited am...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gertz, Morie A., Cohen, Adam D., Comenzo, Raymond L., Kastritis, Efstathios, Landau, Heather J., Libby, Edward N., Liedtke, Michaela, Sanchorawala, Vaishali, Schönland, Stefan, Wechalekar, Ashutosh, Zonder, Jeffrey A., Palladini, Giovanni, Walling, Jackie, Guthrie, Spencer, Nie, Christie, Karp, Carol, Jin, Yuying, Kinney, Gene G., Merlini, Giampaolo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society of Hematology 2023
Materias:	Clinical Trials and Observations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10644097/ https://www.ncbi.nlm.nih.gov/pubmed/37366170 http://dx.doi.org/10.1182/blood.2022019406

Ejemplares similares

P56 SURVIVAL BENEFIT OF BIRTAMIMAB IN MAYO STAGE IV AL AMYLOIDOSIS IN THE PHASE 3 VITAL STUDY WAS CONSISTENT ACROSS ALL KEY BASELINE VARIABLES
por: Gertz, M., et al.
Publicado: (2023)

A randomized phase 3 study of ixazomib–dexamethasone versus physician’s choice in relapsed or refractory AL amyloidosis
por: Dispenzieri, Angela, et al.
Publicado: (2021)

Rationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis
por: Merlini, G, et al.
Publicado: (2016)

Sars-Cov-2 Infection and Systemic Light Chain Amyloidosis: The International Society of Amyloidosis' Survey
por: Milani, Paolo, et al.
Publicado: (2020)

Light Chain Amyloidosis: Patient Experience Survey from the Amyloidosis Research Consortium
por: Lousada, Isabelle, et al.
Publicado: (2015)

Patient experience with hereditary and senile systemic amyloidoses: a survey from the Amyloidosis Research Consortium
por: Lousada, Isabelle, et al.
Publicado: (2015)

Outcomes of renal transplantation in patients with AL amyloidosis: an international collaboration through The International Kidney and Monoclonal Gammopathy Research Group
por: Havasi, Andrea, et al.
Publicado: (2022)

S198: EFFICACY AND SAFETY OF BELANTAMAB MAFODOTIN MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY LIGHT CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORK
por: Kastritis, Efstathios, et al.
Publicado: (2023)

Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis
por: Premkumar, Vikram J., et al.
Publicado: (2021)

P914: EFFICACY AND SAFETY OF BELANTAMAB MAFODOTIN MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY LIGHT CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORK
por: Kastritis, E., et al.
Publicado: (2022)

Outcome of Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis Associated With Deletion of 17p
por: Wong, Sandy W., et al.
Publicado: (2018)

PB2150: CARDIAC AMYLOID REACHING FOR EXTENDED SURVIVAL (CARES) TRIALS: 2 PLACEBO-CONTROLLED, DOUBLE-BLIND, RANDOMIZED, PHASE 3 TRIALS ASSESSING CAEL-101 IN PATIENTS WITH MAYO STAGES IIIA/IIIB AL AMYLOIDOSIS
por: Wechalekar, Ashutosh, et al.
Publicado: (2023)

The management of light chain (AL) amyloidosis in Europe: clinical characteristics, treatment patterns, and efficacy outcomes between 2004 and 2018
por: Palladini, Giovanni, et al.
Publicado: (2023)

Light Chain Amyloidosis
por: Milani, Paolo, et al.
Publicado: (2018)

Novel Therapies in Light Chain Amyloidosis
por: Milani, Paolo, et al.
Publicado: (2017)

Daratumumab in the Treatment of Light-Chain (AL) Amyloidosis
por: Palladini, Giovanni, et al.
Publicado: (2021)

Organ response in patients with AL amyloidosis treated with NEOD001, an amyloid‐directed monoclonal antibody
por: gertz, morie a., et al.
Publicado: (2016)

Outcomes by Cardiac Stage in Patients With Newly Diagnosed AL Amyloidosis: Phase 3 ANDROMEDA Trial
por: Minnema, Monique C., et al.
Publicado: (2022)

Systemic amyloidoses and proteomics: The state of the art
por: Lavatelli, Francesca, et al.
Publicado: (2016)

DUAL expectations in light chain amyloidosis
por: Schönland, Stefan, et al.
Publicado: (2020)

Summary of the EHA-ISA Working Group Guidelines for High-dose Chemotherapy and Stem Cell Transplantation for Systemic AL Amyloidosis
por: Sanchorawala, Vaishali
Publicado: (2022)

A new genetic variant of hereditary apolipoprotein A-I amyloidosis: a case-report followed by discussion of diagnostic challenges and therapeutic options
por: Moutafi, Myrto, et al.
Publicado: (2019)

A validated composite organ and hematologic response model for early assessment of treatment outcomes in light chain amyloidosis
por: Sidana, Surbhi, et al.
Publicado: (2020)

Psychometric validation of the SF-36 Health Survey in light chain amyloidosis: results from community-based and clinic-based samples
por: White, Michelle K, et al.
Publicado: (2017)

Patient-reported burden of hereditary transthyretin amyloidosis on functioning and well-being
por: Lovley, Andrew, et al.
Publicado: (2021)

The lung in amyloidosis
por: Milani, Paolo, et al.
Publicado: (2017)

Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy
por: Adams, David, et al.
Publicado: (2020)

Treatment Options For Relapsed/refractory Systemic Light-Chain (AL) Amyloidosis: Current Perspectives
por: Sarosiek, Shayna, et al.
Publicado: (2019)

P1714: HEALTHCARE RESOURCE UTILIZATION IN PATIENTS WITH LIGHT CHAIN AMYLOIDOSIS IN EUROPE
por: Jaccard, A., et al.
Publicado: (2022)

Waldenström macroglobulinemia treatment algorithm 2018
por: Gertz, Morie A.
Publicado: (2018)

Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2018
por: Gertz, Morie A.
Publicado: (2018)

Correction: Waldenström macroglobulinemia treatment algorithm 2018
por: Gertz, Morie A.
Publicado: (2019)

Role of Daratumumab in Cardiac AL Amyloidosis
por: Gertz, Morie A.
Publicado: (2022)

A longitudinal evaluation of health‐related quality of life in patients with AL amyloidosis: associations with health outcomes over time
por: Sanchorawala, Vaishali, et al.
Publicado: (2017)

How I approach smoldering multiple myeloma
por: Vaxman, Iuliana, et al.
Publicado: (2022)

N‐terminal fragment of the type‐B natriuretic peptide (NT‐proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma
por: Milani, Paolo, et al.
Publicado: (2016)

Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2021
por: Hasib Sidiqi, M., et al.
Publicado: (2021)

Differences in the cytogenetic underpinnings of AL amyloidosis among African Americans and Caucasian Americans
por: Staron, Andrew, et al.
Publicado: (2022)

A Strategy for Synthesis of Pathogenic Human Immunoglobulin Free Light Chains in E. coli
por: Rognoni, Paola, et al.
Publicado: (2013)

Indicators of profound hematologic response in AL amyloidosis: complete response remains the goal of therapy
por: Milani, Paolo, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_uujht2t00dtkh874hmfvi9mjl4